Items where authors include "Herschorn, S."

Article

Herschorn, S., Chapple, C.R. orcid.org/0000-0002-2960-9931, Abrams, P. et al. (8 more authors) (2017) Efficacy and safety of combinations of mirabegron and solifenacin compared with monotherapy and placebo in patients with overactive bladder (SYNERGY study). BJU International, 120 (4). pp. 562-575. ISSN 1464-4096

Herschorn, S., Chapple, C.R. orcid.org/0000-0002-2960-9931, Snijder, R. et al. (2 more authors) (2017) Could Reduced Fluid Intake Cause the Placebo Effect Seen in Overactive Bladder Clinical Trials? Analysis of a Large Solifenacin Integrated Database. Urology, 106. pp. 55-59. ISSN 0090-4295

Drake, M.J., MacDiarmid, S., Chapple, C.R. orcid.org/0000-0002-2960-9931 et al. (8 more authors) (2017) Cardiovascular safety in refractory incontinent patients with overactive bladder receiving add-on mirabegron therapy to solifenacin (BESIDE). International Journal of Clinical Practice, 71 (5). e12944 . ISSN 1368-5031

Sievert, K-D., Chapple, C. orcid.org/0000-0002-2960-9931, Herschorn, S. et al. (4 more authors) (2014) OnabotulinumtoxinA 100U provides significant improvements in overactive bladder symptoms in patients with urinary incontinence regardless of the number of anticholinergic therapies used or reason for inadequate management of overactive bladder. International Journal of Clinical Practice, 68 (10). pp. 1246-1256. ISSN 1368-5031

Chapple, C.R. orcid.org/0000-0002-2960-9931, Nitti, V.W., Khullar, V. et al. (5 more authors) (2014) Onset of action of the beta 3-adrenoceptor agonist, mirabegron, in Phase II and III clinical trials in patients with overactive bladder. World Journal of Urology, 32 (6). pp. 1565-1572. ISSN 0724-4983